59° Sunny

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

38.62 -0.53 (-1.37%)

Streaming Delayed Price Updated: 11:06 AM EDT, Apr 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap? ↗

Today 9:50 EDT

Novo Nordisk stock has been stuck in a downward spiral for quite some time.

Via The Motley Fool

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

Today 6:15 EDT

From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met

From Equity Insider

Via GlobeNewswire

Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗

Today 5:50 EDT

Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

Via The Motley Fool

Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program ↗

April 21, 2026

Telehealth investors weigh Amazon’s new anti-obesity drug push against this platform’s recent rapid growth, today, April 21, 2026.

Via The Motley Fool

Topics Stocks

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗

April 21, 2026

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Via The Motley Fool

Here's Why Agios Pharmaceuticals Crashed 23% Today ↗

April 20, 2026

The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow.

Via The Motley Fool

This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗

April 18, 2026

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

Via The Motley Fool

Topics Intellectual Property Stocks

3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗

April 17, 2026

Via MarketBeat

Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? ↗

April 17, 2026

The stock could have plenty of room to run from current levels.

Via The Motley Fool

Should You Forget CVS Health and Invest in a Purer Healthcare Play? ↗

April 16, 2026

There are other factors to consider before investing in this -- or any other -- healthcare company.

Via The Motley Fool

Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market ↗

April 16, 2026

Lilly's revenue has soared thanks to its obesity drugs.

Via The Motley Fool

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust ↗

April 15, 2026

And can Novo Nordisk catch up to its rival in the weight loss market?

Via The Motley Fool

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Via The Motley Fool

The Global Pantry Reimagined: Unilever and McCormick Seal $65 Billion Merger Deal

April 09, 2026

In a move that has sent shockwaves through the global consumer staples market, Unilever (NYSE:UL) and McCormick & Company (NYSE:MKC) have officially entered into a definitive agreement to merge...

Via MarketMinute

Topics Economy Supply Chain

The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss

April 08, 2026

In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the...

Via MarketMinute

Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker? ↗

April 08, 2026

One of these players is well-positioned for market leadership.

Via The Motley Fool

3 Absurdly Cheap Dividend Stocks to Buy in April 2026 ↗

April 08, 2026

These stocks offer high yields and trade at incredibly low earnings multiples.

Via The Motley Fool

Topics Economy

Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine

April 06, 2026

In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...

Via MarketMinute

Topics Artificial Intelligence

Goldman Sachs Forecasts 12% S&P 500 Surge in 2026: The Five Pillars of a Maturing Bull Market

April 06, 2026

As the second quarter of 2026 kicks off, the investment landscape is being defined by a renewed sense of optimism from Wall Street’s most influential voices. Goldman Sachs (NYSE: GS) has officially...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals? ↗

April 06, 2026

Via MarketBeat

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight ↗

April 04, 2026

The U.S. Food & Drug Administration just approved Eli Lilly's GLP-1 pill orforglipron.

Via The Motley Fool

Earnings Revision Momentum: Why Analysts Upgraded S&P 500 Growth to 17%

April 03, 2026

As of April 3, 2026, the financial landscape is witnessing a historic disconnect between gritty macroeconomic headlines and exuberant corporate fundamentals. Despite a backdrop of stubborn...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market ↗

April 03, 2026

The drugmaker hasn't said its last word yet, as the weight-loss drug battle continues to heat up.

Via The Motley Fool

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

April 03, 2026

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...

Via MarketMinute

Topics Intellectual Property

Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring

April 02, 2026

Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require...

Via MarketMinute

Topics Economy

The Evolution of The Cigna Group: A Deep Dive into a Health Services Powerhouse (2026)

April 02, 2026

April 2, 2026 Introduction The Cigna Group (NYSE: CI) stands today at a pivotal crossroads, having undergone one of the most significant strategic transformations in the modern healthcare era. Long...

Via Finterra

Topics Artificial Intelligence Economy Lawsuit

The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)

April 02, 2026

As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Why Eli Lilly Stock Trounced the Market Today ↗

April 01, 2026

Its first weight-loss pill was just approved by the FDA.

Via The Motley Fool

Eli Lilly’s $47.8 Billion Masterstroke: The Contessa Acquisition and the New Era of Pharmaceutical Dominance

April 01, 2026

INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire...

Via MarketMinute

Topics Artificial Intelligence Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Sections

Services